Real world comparison of spironolactone and eplerenone in patients with heart failure

Authors :: Patricia Pardo-Martínez
Eduardo Barge-Caballero
Alberto Bouzas-Mosquera
Gonzalo Barge-Caballero
David Couto-Mallón
María J. Paniagua-Martín
Marta Sagastagoitia-Fornie
Óscar Prada-Delgado
Javier Muñiz
Luis Almenar-Bonet
José M. Vázquez-Rodríguez
María G. Crespo-Leiro
Source :: EUROPEAN JOURNAL OF INTERNAL MEDICINE, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname, RUC. Repositorio da Universidade da Coruña
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.
Abstract: [Abstract] Aims. In the absence of previous direct comparative studies, we aimed to evaluate the effectiveness of spironolactone and eplerenone in patients with heart failure and reduced ejection fraction (HFrEF) in a real-world clinical setting. Methods. Using Fine-Gray´s competing risk regression, we compared the clinical outcomes of 293 patients with chronic HF and left ventricular ejection fraction

Subjects :: Heart Failure
Survival
Stroke Volume
Heart failure
Outcomes
Spironolactone
Ventricular Function, Left
Eplerenone
Ventricular Dysfunction, Left
Reduced ejection fraction
Treatment Outcome
Internal Medicine
Humans
Prospective Studies
Mineralocorticoid Receptor Antagonists

Tools